Wednesday, April 24, 2024 4/24/2024

scaRNA Modified Induced Pluripotent Stem Cell-Derived Cardiomyocytes or Exosomes Therapy for Chronic Ischemic Cardiomyopathy Patients

Award Number: R01HL141345
ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Group Awards By Issue Date FY or Funding FY:

View Award Abstract

PROJECT SUMMARY Ischemic cardiomyopathies (ICM) continue to be among the leading causes of death in Western countries. Currently, 5.7 million Americans are living with heart failure, and about 10% have advanced heart failure. Although, many important advances in the treatment of heart failure have evolved during the last decade, most focus only on relieving symptoms and preventing disease progression. Thus, an improved treatment or curative regimen is desperately needed. Our long-term goal is to develop an effective therapeutic intervention for ICM that will improve and prolong the lives of millions of people, and potentially eliminate their disease. Cardiac repair with stem cell therapy has emerged as a promising treatment alternative for the ischemic patient population. Successful generation of induced pluripotent stem cells (iPSCs) and their differentiation into induced- cardiomyocytes (iCMCs) have created exciting possibilities, wherein iCMCs may offer a renewable cell source for therapy, disease modeling and drug discovery. We have generated a safe combinatorial approach using DNA and mRNA of pluripotent factors to reprogram normal urinary epithelial (UE) cells into iPSCs, with subsequent differentiation into functional iCMCs as described by us earlier. Recently, our RNA sequencing analysis of iCMC indicated that small cajal body associated RNA20 (scaRNA20) plays an important—and so far, understudied- role in CMC differentiation. We also found that early-stage (day 7) and mid-cardiac progenitor cell (CPC) stage (day 14), and late-stage (day 21) iCMCs exhibit different potential for cell transplantation. Our preliminary data favors the day 14 (CPC/iCMC) stage for the transplantation with regards to the maturity and its differentiation potential into cardiomyocytes, endothelial cells and smooth muscle cells. Recent results also indicate the important roles of exosomes (stem cell- or progenitor- derived) play in tissue regeneration. Based on these observations, our central hypothesis states that overexpressing scaRNA20 during iCMCs differentiation and selecting an appropriate differentiation stage (day 14) for cell or exosome treatment would induce superior cardiac repair in the ICM patients. We plan to test our hypothesis by pursuing the following three specific aims. (1) To characterize cardiomyocytes induced from urinary epithelial cells (UE-iCMCs) and determine the role of scaRNAs during differentiation of iPSCs into iCMCs. (2) To determine the therapeutic efficiency of scaRNA20 modulated iCMCs in a SCID mouse chronic ischemic cardiomyopathy (ICM) model. (3) In vitro and in vivo analysis of the paracrine mechanisms of scaRNA20 modulated UE-iCMCs and their exosomes. If successful, this approach will dramatically enhance our ability to perform autologous cell or cell-free exosome therapy for patients with no-option heart diseases.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = -$135,925 )
2024	2022	UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE, INC.	3901 RAINBOW BLVD	KANSAS CITY	KS	66160	WYANDOTTE	USA	Cardiovascular Diseases Research	000	4	4/8/2024	NON-COMPETING CONTINUATION	-$135,925
														Subtotal = -$135,925

Issue Date FY: 2022 ( Subtotal = $369,497 )
2022	2022	UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE, INC.	4330 SHAWNEE MISSION PKWY	SHAWNEE MISSION	KS	66205	JOHNSON	USA	Cardiovascular Diseases Research	001	4	6/18/2022	NON-COMPETING CONTINUATION	$36,950
2022	2022	UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE, INC.	4330 SHAWNEE MISSION PKWY	SHAWNEE MISSION	KS	66205	JOHNSON	USA	Cardiovascular Diseases Research	000	4	12/2/2021	NON-COMPETING CONTINUATION	$332,547
2022	2019	UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE, INC.	3901 RAINBOW BLVD	KANSAS CITY	KS	66160	WYANDOTTE	USA	Cardiovascular Diseases Research	002	1	9/26/2022	NEW	$0
														Subtotal = $369,497

Issue Date FY: 2021 ( Subtotal = $372,903 )
2021	2021	UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE, INC.	4330 SHAWNEE MISSION PKWY	SHAWNEE MISSION	KS	66205	JOHNSON	USA	Cardiovascular Diseases Research	000	3	11/25/2020	NON-COMPETING CONTINUATION	$335,612
2021	2021	UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE, INC.	4330 SHAWNEE MISSION PKWY	SHAWNEE MISSION	KS	66205	JOHNSON	USA	Cardiovascular Diseases Research	001	3	5/24/2021	NON-COMPETING CONTINUATION	$37,291
														Subtotal = $372,903

Issue Date FY: 2020 ( Subtotal = $380,000 )
2020	2020	UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE, INC.	4330 SHAWNEE MISSION PKWY	SHAWNEE MISSION	KS	66205	JOHNSON	USA	Cardiovascular Diseases Research	000	2	1/29/2020	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$380,000
2020	2020	UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE, INC.	4330 SHAWNEE MISSION PKWY	SHAWNEE MISSION	KS	66205	JOHNSON	USA	Cardiovascular Diseases Research	003	2	5/7/2020	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$281,938
2020	2019	UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE, INC.	4330 SHAWNEE MISSION PKWY	SHAWNEE MISSION	KS	66205	JOHNSON	USA	Cardiovascular Diseases Research	002	1	5/7/2020	NEW	-$281,938
2020	2019	UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE, INC.	4330 SHAWNEE MISSION PKWY	SHAWNEE MISSION	KS	66205	JOHNSON	USA	Cardiovascular Diseases Research	001	1	1/30/2020	NEW	$0
														Subtotal = $380,000

Issue Date FY: 2019 ( Subtotal = $382,500 )
2019	2019	UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE, INC.	4330 SHAWNEE MISSION PKWY	SHAWNEE MISSION	KS	66205	JOHNSON	USA	Cardiovascular Diseases Research	000	1	12/20/2018	NEW	$382,500
														Subtotal = $382,500

Grand Total All Awards = $1,368,975

Top

All Categories

About

Search

Reports

Data Submission

Award Information

scaRNA Modified Induced Pluripotent Stem Cell-Derived Cardiomyocytes or Exosomes Therapy for Chronic Ischemic Cardiomyopathy Patients

Award Number: R01HL141345

ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer